GlassScriptPhysician profile
Christina E Lillywhite
NPI 1295467181
$1,954.68
in general payments reported to CMS, 2019-2025
28 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.50 · 2023: $863 · 2024: $612 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840 · Education: $59.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,840.26 |
| Education | $59.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $253.69 | 2023-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $249.77 | 2023 | Dupixent |
| Phathom Pharmaceuticals, INC. | $197.60 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $188.11 | 2023-2025 | Vemlidy |
| Qol Medical, LLC | $126.86 | 2023 | Sucraid |
| Madrigal Pharmaceuticals | $100.75 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $88.70 | 2023-2024 | Xarelto |
| Abbvie INC. | $88.21 | 2023-2025 | |
| Ardelyx, INC. | $78.91 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $59.92 | 2024 | Zymfentra |
| Glaxosmithkline, LLC. | $59.70 | 2022-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $56.32 | 2023 | Fasenra, Bevespi Aerosphere |
| Lilly USA, LLC | $48.33 | 2023 | Mounjaro |
| Intercept Pharmaceuticals, INC. | $42.85 | 2024 | |
| Celgene Corporation | $42.59 | 2024 | Zeposia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.04 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $29.63 | 2024 | |
| Merck Sharp & Dohme LLC | $23.48 | 2023 | Rotateq, Vaxneuvance, Vaxelis |
| Ironwood Pharmaceuticals, INC | $23.29 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.19 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.68 | 2023 | Xtampza |
| Janssen Biotech, INC. | $21.29 | 2025 | Tremfya |
| Vivus LLC | $18.58 | 2025 | Pancreaze |
| Axsome Therapeutics, INC. | $16.39 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.74 | 2023 | Quviviq |
| Novo Nordisk INC | $15.62 | 2023 | |
| Amarin Pharma, INC. | $13.99 | 2023 | |
| Amgen INC. | $13.45 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Lillywhite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.